PDUFA VI Might Adjust Establishment Fees; FDA Aims For Simplification
This article was originally published in The Tan Sheet
Executive Summary
User fees would need significant restructuring to make up revenue if establishment fees are eliminated, or even just changed, as part of reauthorization. As part of FDA-industry negotiations, several small working groups are expected to be created to deal with specific issues.
You may also be interested in...
The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Agency will substantially reduce amount of human drug and biosimilar user fees that it carries over from year to year by the end of fiscal 2022; carryover generic drug and biosimilar fees will go toward hiring term-limited employees and building capacity, but a technical issue will keep FDA from accessing $79m in PDUFA fees.
The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Agency will substantially reduce amount of human drug and biosimilar user fees that it carries over from year to year by the end of fiscal 2022; carryover generic drug and biosimilar fees will go toward hiring term-limited employees and building capacity, but a technical issue will keep FDA from accessing $79m in PDUFA fees.
PDUFA Negotiations Begin With FDA Seeking Review System Reform
Fee structure changes and process enhancements floated during opening session between industry and agency.